ArticleBMC pharmacology & toxicology2025
Ultrasound stimulated microbubble cavitation promoted the anticancer effect of Lenvatinib on anaplastic thyroid cancer.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAnaplastic thyroid cancer (ATC) is an extremely aggressive subtype of thyroid cancer associated with poor prognosis. Thus, the necessity to develop innovative treatment approaches is critical. Lenvatinib is the one of the drugs approved for ATC in clinic, however, its efficacy is limited. The present study investigated the combined effect of ultrasound stimulated microbubble cavitation (USMC) and Lenvatinib on tumor growth.
methodsUndifferentiated thyroid carcinoma C643 cells were subcutaneously inoculated into mice to establish transplanted tumor model and mice were allocated into 4 groups (model group, Lenvatinib group, USMC group, and Lenvatinib + USMC group). Blood perfusion in tumors was estimated with contrast-enhanced ultrasound (CEUS) and the microvascular structures were observed by transmission electron microscopy. H&E and Masson staining was applied. Immunohistochemical staining for CD31, Ki67, Caspase 3 expression, ELISA for VEGFA, NO, and PGF2 levels, western blot for HIF-1α and Akt/PI3K proteins, and immunofluorescence for VEGFA and ICAM-1.
resultsUSMC caused mild enlargement and congestion of tumor microvessels. Moreover, upon exposure to USMC, the area under the curve and peak intensity of CEUS (MI = 0.4) showed an increase, indicating that USMC has the potential to augment blood flow within tumors. The combination of USMC and Lenvatinib meaningfully suppressed tumor growth, induced apoptosis, inhibited Ki67 expression and extended the survival of mice bearing C643 tumor. USMC also improved the anti-angiogenesis effect of Lenvatinib, as demonstrated by decreased expression of collagen fiber, CD31, HIF-1α and VEGFA in tumors and inactivation of PI3K/Akt pathway. Increment in ICAM-1, PGF
conclusionsThese results indicated that the combination of Lenvatinib and USMC could serve as a promising and innovative method for ATC therapy, surpassing the effectiveness of Lenvatinib monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.